Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. One of the best biotech stocks on our list is Altimmune, Inc.

TheFly reported on January 27 that Barclays initiated coverage of ALT with an Overweight rating and a $20 price target. Strong underlying fundamentals, continuous merger and acquisition activity, and alleviating medication pricing concerns are the reasons behind the firm’s optimistic outlook for the biotech industry in 2026. Additionally, Barclays pointed out that ALT and other biotech stocks are still cheap in comparison to their pipeline potential.

Altimmune, Inc. (NASDAQ:ALT) also announced on the same day that it intends to use the net proceeds from the offering for working capital, general company needs, and getting ready for its next Phase 3 MASH research. The FDA’s Breakthrough Therapy Designation and positive Phase 2b 48-week findings bolster the company’s claim that pemvidutide is a novel glucagon/GLP-1 dual agonist.

Altimmune, Inc. (NASDAQ:ALT) is a clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for metabolic and liver diseases, including obesity and metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, pemvidutide, targets GLP-1 and glucagon receptors to reduce weight, liver fat, and cardiometabolic risk.

While we acknowledge the potential of ALT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.